Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315673 | 1.00 | CYP3A4 (0.40) | CYP3A4HSD17B1HSD17B2ADAMTS5ACKR3 | |
| SCHEMBL6322627 | 0.93 | ACKR3 (0.40) | HSD17B1HSD17B2ACKR3TP53 | |
| SCHEMBL6322629 | 0.93 | ACKR3 (0.40) | HSD17B1HSD17B2ACKR3TP53 | |
| SCHEMBL6318993 | 0.93 | ACKR3 (0.38) | CYP3A4ADAMTS5ACKR3PPARA | |
| SCHEMBL6318988 | 0.93 | ACKR3 (0.38) | CYP3A4ADAMTS5ACKR3PPARA | |
| SCHEMBL6319513 | 0.92 | ADAMTS5 (0.37) | CYP3A4ADAMTS5PPARA | |
| SCHEMBL6320085 | 0.92 | ADAMTS5 (0.37) | CYP3A4ADAMTS5PPARA | |
| SCHEMBL6316826 | 0.91 | ERCC5 (0.39) | CYP3A4ADAMTS5PPARA | |
| SCHEMBL6316819 | 0.91 | ERCC5 (0.39) | CYP3A4ADAMTS5PPARA | |
| SCHEMBL6318307 | 0.91 | RORC (0.39) | ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | claimed |
| EP-1395571-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Shire Biochem Inc. (CA) | 2004-03-10 | — | — | EP | claimed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | claimed |
| WO-2002100846-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SHIRE BIOCHEM INC. (CA) | 2002-12-19 | — | — | WO | claimed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | disclosed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | HAVCR2, ZC3HAV1, MAVS | CYP3A4 452/4885HSD17B1 450/4885HSD17B2 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.